146 related articles for article (PubMed ID: 10660737)
21. Raltitrexed: optimism and reality.
Wilson KS; Malfair Taylor SC
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
[TBL] [Abstract][Full Text] [Related]
22. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
[TBL] [Abstract][Full Text] [Related]
23. [Non-alcoholic steatohepatitis with cirrhosis after raltitrexed administration].
Flamenbaum M; Kemeny JL; Garcia V; Artigue F; Buffet C; Cassan P
Gastroenterol Clin Biol; 2001 Feb; 25(2):200-1. PubMed ID: 11319446
[No Abstract] [Full Text] [Related]
24. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Beale P; Judson I; Hanwell J; Berry C; Aherne W; Hickish T; Martin P; Walker M
Cancer Chemother Pharmacol; 1998; 42(1):71-6. PubMed ID: 9619761
[TBL] [Abstract][Full Text] [Related]
25. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
26. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
Tsavaris N; Kosmas C; Vadiaka M; Kontos A; Fotia M; Angelopoulou A; Vrizidis N; Soulla M; Sougioultzis S; Koufos Ch
Invest New Drugs; 2002 Feb; 20(1):133-6. PubMed ID: 12003191
[TBL] [Abstract][Full Text] [Related]
27. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
Smith I; Jones A; Spielmann M; Namer M; Green MD; Bonneterre J; Wander HE; Hatschek T; Wilking N; Zalcberg J; Spiers J; Seymour L
Br J Cancer; 1996 Aug; 74(3):479-81. PubMed ID: 8695369
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
31. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
32. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer.
Botwood N; James R; Vernon C; Price P
Ann Oncol; 2000 Aug; 11(8):1023-8. PubMed ID: 11038040
[TBL] [Abstract][Full Text] [Related]
33. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 2000 Jul; 72(1):112-4. PubMed ID: 10979221
[No Abstract] [Full Text] [Related]
34. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
[TBL] [Abstract][Full Text] [Related]
35. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Clarke SJ; Hanwell J; de Boer M; Planting A; Verweij J; Walker M; Smith R; Jackman AL; Hughes LR; Harrap KR; Kennealey GT; Judson IR
J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.
Pazdur R; Meropol NJ; Casper ES; Fuchs C; Douglass HO; Vincent M; Abbruzzese JL
Invest New Drugs; 1996; 13(4):355-8. PubMed ID: 8824356
[TBL] [Abstract][Full Text] [Related]
38. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Jerusalem G; Bours V; Fillet G
Rev Med Liege; 1998 Jun; 53(6):318-21. PubMed ID: 9713208
[TBL] [Abstract][Full Text] [Related]
39. [Phase II study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) in gastrointestinal cancer].
Takenaka K; Tamada R; Hiramoto Y; Inokuchi K; Saku M; Oka N; Kano T; Noda S; Nagasaki S; Toda T
Gan To Kagaku Ryoho; 1985 Nov; 12(11):2155-60. PubMed ID: 4062315
[TBL] [Abstract][Full Text] [Related]
40. Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group.
Muggia FM; Blessing JA; Homesley HD; Sorosky J
Cancer Chemother Pharmacol; 1998; 42(1):68-70. PubMed ID: 9619760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
